Diagnosis and treatment of systemic sclerosis-associated interstitial lung disease: current status and advances
- VernacularTitle: 系统性硬化症相关间质性肺病的诊治现状和进展
- Author:
Binglin CHEN
1
;
Meijuan XUE
;
Ji YANG
;
Ming LI
Author Information
- Publication Type:Review
- Keywords: Scleroderma, systemic; Lung diseases, interstitial; Diagnosis; Clinical protocols
- From: Chinese Journal of Dermatology 2020;53(1):66-71
- CountryChina
- Language:Chinese
- Abstract: Systemic sclerosis (SSc) is a rare, chronic connective tissue disease with internal organ fibrosis, and interstitial lung disease (ILD) is the leading cause of death in patients with SSc. The onset of SSc-associated ILD is usually latent, and delayed treatment may lead to rapid progression, and markedly decrease the quality of life and survival rate of patients. This review summarizes approaches to the early diagnosis of SSc-associated ILD and the time-to-treatment, and provides an overview of its treatment, including traditional immunosuppressive agents, newly emerging targeted therapies, hematopoietic stem cell transplantation, lung transplantation, and so on.
